23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
01:35 , Feb 1, 2019 |  BC Week In Review  |  Company News

Ahead of 2019 milestones, Aslan reduces headcount, operating costs

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Jan. 29 it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on...
23:00 , Jan 29, 2019 |  BC Extra  |  Company News

Aslan to reduce headcount, operating costs to support upcoming milestones

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Tuesday it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on its...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Aslan, CSL deal

Aslan gained worldwide rights to CSL334 ( ASLAN004 ) from CSL. The human mAb against IL-13 receptor alpha 1 ( IL-13RA1 ; IL-13Ra ; CD213A1 ) is in preclinical testing to treat asthma. Aslan will...
07:00 , May 19, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) gained $1.85 to $33.22 last week after submitting an NDA to FDA for deoxycholic acid (ATX-101) to reduce submental (under chin) fat. Kythera plans to submit ex-U.S. regulatory applications...
01:30 , May 14, 2014 |  BC Extra  |  Company News

Aslan gains rights to preclinical asthma product from CSL

Aslan Pharmaceuticals Pte. Ltd. (Singapore) gained worldwide rights to CSL334 from CSL Ltd. (ASX:CSL). The human mAb against IL-13 receptor alpha 1 (IL-13RA1; IL-13Ra; CD213A1) is in preclinical testing to treat asthma. Aslan will fund...